Skip to content
Dr Matthew Baker

Dr Matthew Baker

Non-Executive Director

Dr Baker has a background in immunology with >15 years experience in developing biologics (for biotech and pharma companies), and has a successful track record of implementing M&A's and IPO exit strategies.

Dr Baker currently holds positions as CSO at Denceptor (Cambridge, UK) and VP Immunology & Oncology at Celentyx (Birmingham, UK).

Previous positions include CSO at Abzena, CEO/CSO (and co-founder) of Antitope, and VP Biologics Discovery at Biovation (subsidiary of Merck KGaA). Pre-industry experience includes postdoctoral positions in Cambridge and a PhD in cellular immunology from University of Birmingham UK.

We use cookies to give you the best experience of using this website. By continuing to use this site, you accept our use of cookies. Please read our Cookie Policy for more information.

Our single technology platform that fully connects our smart labs with our customer service proposition.


Connex revolutionises DNA design, optimization and assembly by ensuring the highest levels of quality control, efficiency and project management available for any client.

OXGENE has fully integrated all its smart labs and robotic production processes within a single technology platform that allows real-time project updates for our customers.